Catabasis Pharmaceuticals, Inc. (CATB) Analysts See $-0.27 EPS

July 14, 2018 - By Andrea Pope

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) Logo

Analysts expect Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) to report $-0.27 EPS on August, 9.They anticipate $0.05 EPS change or 15.63 % from last quarter’s $-0.32 EPS. After having $-0.29 EPS previously, Catabasis Pharmaceuticals, Inc.’s analysts see -6.90 % EPS growth. The stock decreased 3.24% or $0.03 during the last trading session, reaching $0.85. About 314,872 shares traded. Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) has risen 16.91% since July 14, 2017 and is uptrending. It has outperformed by 4.34% the S&P500.

Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic products based on safely metabolized and rationally targeted linker drug discovery platform in the United States. The company has market cap of $60.38 million. The firm offers Edasalonexent, an investigational oral small molecule, which is in Phase I/II clinical trial for the treatment of duchenne muscular dystrophy (DMD). It currently has negative earnings. It is also involved in developing SMART linker conjugates that are in preclinical stage of development, including CAT-5571 for cystic fibrosis (CF) trafficking and function of CF transmembrane conductance regulator, as well as for the clearance of Pseudomonas aeruginosa; and CAT-4001 for the treatment of severe and rare neurodegenerative diseases, such as Friedreich's ataxia and amyotrophic lateral sclerosis.

More recent Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) news were published by: Streetinsider.com which released: “Catabasis Pharma (CATB) Announces Plans for Edasalonexent Phase 3 POLARIS DMD Trial in DMD” on July 09, 2018. Also Benzinga.com published the news titled: “Benzinga’s Daily Biotech Pulse: AbbVie Files sNDA For Leukemia Drug, AcelRx Offering, Aurinia Starts Mid-Stage Trial” on July 12, 2018. Nasdaq.com‘s news article titled: “Analysis: Positioning to Benefit within The Manitowoc, Omeros, Catabasis Pharmaceuticals, Zayo Group, Covanta …” with publication date: June 26, 2018 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.